ABSTRACT. Newly identified forms of electron transfer flavoprotein (ETF) deficiency in two patients with glutaric aciduria type I1 (GA 11) were described. GA I1 has been attributed to a defect of either ETF or ETF dehydrogenase, resulting in multiple acyl-CoA dehydrogenation deficiency. ETF is a mitochondrial flavoprotein consisting of an asubunit, a-ETF, and a @-subunit, 0-ETF. We used pulsechase experiments to examine the biosynthesis of ETF in fibroblasts from two patients with GA 11. Patient 1 was a boy with the neonatal onset form, but without congenital anomalies, who is living at age 2 y. A defect of B-ETF biosynthesis was noted in this patient. Patient 2 was a boy with the neonatal onset form with congenital anomalies who died on the 3rd postnatal day. He presented with a peculiar face and polycystic kidneys. In patient 2, both aand B-ETF were synthesized, but both the subunits were rapidly degraded. The lability of ETF was considered to be the cause of GA I1 in this patient. These two cases appear to be new forms of ETF deficiency in GA 11. (Pediatr Res 29: 60-63,1991) Abbreviations GA 11, glutaric aciduria type I1 ETF, electron transfer flavoprotein a-ETF, a-subunit of ETF 8-ETF, B-subunit of ETF pa-ETF, precursor of a-ETF ETF-DH, electron transfer flavoprotein dehydrogenase GC/MS, gas chromatography and mass spectrometry R6G, rhodamine 6G GA 11, first described in 1976 (I), is an inherited disorder of organic acid metabolism caused by metabolic blocks at several steps of mitochondrial flavin-containing acyl-CoA dehydrogenases: short-chain acyl-CoA dehydrogenase, medium-chain acylCoA dehydrogenase, or long-chain acyl-CoA dehydrogenase involved in fatty acid P-oxidation; isovaleryl-CoA dehydrogenase, isobutyryl-CoA dehydrogenase, and methylbutyryl-CoA dehy- drogenase involved in branched-chain amino acid catabolism; glutaryl-CoA dehydrogenase in lysine, hydroxylysine, or tryptophan catabolism; and sarcosine dehydrogenase (2). Many patients with GA I1 present with hypotonia, tachypnea, hypoglycemia, and, often, neonatal death, or Reye's syndrome-like illness. Urinary organic acid analysis by GC/MS shows an increased excretion of characteristic compounds such as adipate, suberate, sebacate, glutarate, Zhydroxyglutarate, ethylmalonate, or isovalerylglycine, which are the corresponding metabolites derived from defective steps (2). The etiology of this disorder was postulated to be due to deficiency of a protein component common to acyl-CoA dehydrogenation (2-1 1).
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A genetic deficiency of ETF or ETF-DH in GA I1 was demonstrated by enzyme assay, immunoblotting, or pulse-labeling techniques (1 [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . ETF is a heterodimeric flavoprotein consisting of two subunits, an a-subunit (a-ETF) and a P-subunit (P-ETF), localized in the mitochondrial matrix (15) (16) (17) . We now describe two new forms of ETF deficiency in patients with GA 11, identified in pulse-chase experiments. In one patient there seems to be a defect in 8-ETF biosynthesis, and in the other, lability of the ETF subunits seems to be the cause.
MATERIALS AND METHODS
Fibroblasts. Skin fibroblasts obtained from two Japanese children with GA 11, patients l and 2, were cultured in Eagle's minimal essential medium containing 10% FCS (vol/vol) and antibiotics (standard medium).
Patient I was a boy born to unrelated parents, and the family history was noncontributory. He was diagnosed with GA I1 at the age of 10 mo, based on the results of the urinary organic acids analyzed by GC/MS. Urinary organic acids such as dicarboxylic acids (adipate, suberate, and sebacate), 2-hydroxy-glutarate, isovalerylglycine, and ethylmalonate were elevated. He had transient respiratory distress in the neonatal period and a mild gross motor retardation was evident in early infancy. At 5 mo of age, hypotonia, tachypnea, vomiting, hypoglycemia, and metabolic acidosis occurred after an infection. Subsequently, similar episodes occurred several times after an infection or a bout of diarrhea. Patient 2 was a boy born to unrelated parents. His brother had died of unknown causes 12 h after delivery. This patient died on the 3rd postnatal day, with apnea, hypotonia, lethargy, vomiting, and a peculiar body odor. Laboratory test revealed hypoglycemia, metabolic acidosis, and hyperammonemia. Urinary organic acids analysis by GC/MS revealed an increased excretion of adipate, sebacate, glutarate, ethylmalonate, 2-hydroxy-glutarate, and isovalerylglycine. An enlarged head and anterior fontanel were also Immunoblot analysis of ETF. Figure 1 summarizes the results Preparation 0fETF and the antibody. ETF was purified from of immunoblot analysis of ETF. The bands for a-and B-ETF rat liver, and the antibody against rat ETF was raised in rabbits were clearly seen in the human liver tissue (Fig. 1, lane 2) and and partially purified as described (1 5).
the control fibroblasts (Fig. 1, lanes 3 and 6) . In both patients, Immunoblot a n a l y~i~. Fibroblast extracts were applied to SDS/ bands for a-and 0-ETF were not detected (Fig. 1, lanes 4 and 5, PAGE, and immunoblotting was then done as described (18) respectively). Other fainter bands may be due to nonspecific using the system recommended in the supplier's instructions.
reactions.
Pulse-labeling and chase experiment. Fibroblasts were grown
Pulse-labeling of precursor and mature subunits of ETF. Culin 6-cm plastic dishes. Pulse-labeling was performed as described tured fibroblasts were incubated for 1 h with [35S]methionjne in (1 8) using 200 P C~ of [3SSlmethionine Per each dish. When R6G, the presence and the absence of R6G, an inhibitor of mitochonan inhibitor of transport of the precursors of the mitochondrial drial import of the precursor proteins. Figure 2 summarizes the enzymes and their ~rocessing (19) was used, it was added to the results. In the control fibroblasts, the fluorographic bands for the medium to give a final concentration of S/*g/mL 30 min after mature form of a-ETF and P-ETF were apparent in the absence start of the preincubation, and to the labeling medium, as de-of R6G (Fig. 2, lane 3) . In the presence of R6G, pa-ETF was scribed (20,2 1 ). In pulse-chase experiments, the labeling n~edium observed migrating slightly slower than the corresponding mature was replaced with 3 mL of the standard medium after a I-h counterpart. The P-ETF precursor migrated at the same position pulse-labeling, then the cells were chased for 6 h, 24 h, and 72 as the mature subunit detected in the absence of R6G (Fig. 2 , h, respectively, as described (1 8).
lane 2). The competition experiment with purified rat ETF gave ImmunoPreciPitation andfluorogra~h~. The labeled and $01~-no band (Fig. 2, lane 1) or a fainter band (Fig. 2, lane 4) . After bilized cells were treated as dfxribed ( 1 8), and immunoprecipi-fibroblasts from patient 1 were pulse-labeled, the signals for the tated with anti-[rat ETFIIgG. For competition experiment, about p a -E T~ and a-ETF were clearly seen in the presence and the 5rg of purified rat ETF was added before incubating with the absence of R6G, respectively, but no bands for @-ETF were R L C PI P2 C' detected in either lane (Fig. 2, lanes 6 and 7) . In fibroblasts from patient 2, signals for pa-ETF, a-ETF, and 0-ETF were obtained (Fig. 2, lanes 10 and I I) , as in the normal control. These findings a-ETFL suggest that patient 1 has a defect in the biosynthesis of @-ETF. However, in patient 2, synthesis of both a-and P-ETF seemed normal.
B -E T F~
Pulse-chase experiments. Chase experiments were performed for 6 h, 24 h, and 72 h after pulse-labeling for 1 h to examine the stability of synthesized subunits of ETF. the results. In the normal control, the signals for both a-and 0-ETF were observed after a 72-h chase ( Fig. 3A and B, lanes I- Fig. 1 . Immunoblot analysis of ETF. Lane 1, purified rat ETF (5 ng 4). In patient 1, a-ETF band was visible after a 6-h chase (Fig.  of protein applied) ; lanes 2 and 7, human liver (10 Kg each of protein); 3A, lanes 5 and 6) but could not be detected after a longer chase lanes 3 and 6, control fibroblasts (50 pg each of protein); lanes 4 and 5, (Fig. 3A, lanes 7 and 8) . NO band for the P-ETF was present in fibroblasts of patient 1 and patient 2, respectively (50 pg each of protein). any lane (Fig. 3A, lanes 5-8) . For patient 2, the bands for a-and R, rat ETF; L, human liver; C and C', two different control fibroblast P-ETF were seen at a 6-h chase, but both bands disappeared after lines; P, and P2, fibroblasts from patient 1 and patient 2, respectively. a 24-h chase (Fig. 3B, lanes 5-8) . 1-4) ; pand B, patient 2 (lanes 5-8) and normal control (lanes 1-4) . Lanes I and 5, pulse-labeling with 200 pCi of ["S]methionine for I h; lanes 2 and 6, chase for 6 h; lanes 3 and 7, chase for 24 h; lanes 4 and 8, chase for 72 h. P, pulse-labeled for 1 h; 6, 24, and 72, chased for 6, 24, and 72 h, respectively, after I h pulselabeling. 5-8) and normal control (lanes 1-4) ; panel B, patient 2 (lanes [5] [6] [7] [8] and normal control (lanes 1-4) . Abbreviations are the same as those in Figure 3 . Arrows indicate the position of the thiolase.
3-ketoacyl-CoA thiolase were prepared as the positive control of the mitochondrial enzyme protein, using the same samples. As shown in Figure 4 , signals were clearly observed after a 72-h chase, the intensity being the same for fibroblasts from the control and the patients. These findings indicate that the primary defect in patient 1 is P-ETF biosynthesis. The 8-ETF deficiency may secondarily cause lability of a-ETF, as assembly of the ETF complex in the mitochondria would not occur. In patient 2, both a-and P-ETF were synthesized, but were unstable. This lack of stability is likely to cause GA 11.
DISCUSSION
GA 11, also known as multiple acyl-CoA dehydrogenation deficiency, is characterized by severe acidosis, hypoglycemia, or Reye's syndrome-like illness (2) . GA I1 may be caused by a defect in either ETF or ETF-DH involved in mitochondrial acyl-CoA dehydrogenases (2, 12, 13) . ETF-DH deficiency has been described by enzyme assay and immunoblot analysis (12, 14) , and an ETF deficiency was also shown by immunoblotting (12, 14) , pulse-labeling (1 3), or measurement of ETF activity (23) .
ETF is a heterodimer consisting of an a-and a @-subunit, which are encoded by different nuclear genes, translated on cytosolic polyribosomes as precursors, and translocated into mitochondria: functional ETF is formed by assembly of a-and 8-ETF in the mitochondrial matrix (1 5-1 7), as with many other mitochondrial matrix enzymes (24) (25) (26) . Human a-ETF is translated as a precursor of the 35 kD, which is 3 kD larger than the mature a-ETF. cDNA for human a-ETF precursor was cloned by Finocchiaro et al. (27) . P-ETF, synthesized in the cytosol(27 kD), is indistinguishable in size from the mature form (1 3).
Frerman and Goodman (12) analyzed six cell lines from GA I1 patients by determining the ETF-DH activity and immunoblot analysis of ETF and ETF-DH. They concluded that four of the six lines were related to an ETF-DH deficiency and the other two had an ETF deficiency. The latter two cell lines were reported to have small amounts of an abnormal a-ETF and migration was faster on SDS/PAGE than it was for the normal a-ETF. One cell line (their 1441) had a normal amount of P-ETF but another (their 1196) had no P-ETF. Ikeda el al. (13) also studied the biosynthesis of ETF in eight cell lines from GA I1 patients, using pulse-labeling techniques. They showed that three lines had defects in a-ETF biosynthesis, and that one (Ikeda's 605; Frerman's 1 196) from a patient reported by Przyrembel et a[. (1) had normal P-ETF but no a-ETF. Frerman and Goodman (12) reported that the cell line (their 1 196) had abnormal a-ETF and no 8-ETF, as determined by immunoblot analysis. Although the reason for this discrepancy is unclear, a possible primary defect of a-ETF biosynthesis in this cell line might have been identified in pulse-labeling experiments. Although immunoblotting is a simpler method for the detection of the ETF deficiency, it reveals only the antigen peptide at the steady state. On the other hand, pulse-chase experiments examine both polypeptide synthesis and stability. In our study, no ETF subunits were detected for either patient by immunoblotting, yet the results of pulse-chase experiments showed that either or both of the subunits of ETF were translated normally.
A genetic deficiency of either ETF or ETF-DH deficiency has been identified in GA I1 patients (12) (13) (14) . Cases of a-ETF deficiency were described by Frerman and Goodman (12) using immunoblotting, and by Ikeda et al. (13) , using pulse-labeling. Immunoblotting was used by Loehr et al. (14) to identify P-ETF deficiency. Patient 1 in this report is apparently the first reported case of a defect in P-ETF biosynthesis to be demonstrated by pulse-chase experiments. As described above, in this patient, the lability of a-ETF may also be caused by 8-ETF deficiency. Degradation of a-ETF in this patient appears to be occuning inside the mitochondria, given that the transit peptide cleavage occurred in experiments using R6G, an inhibitor of transport of the precursor of mitochondrial enzymes. On the other hand, in patient 2, both a-and P-ETF were synthesized but both the subunits were degraded rapidly. In patient 2, mitochondrial degradation of ETF subunits also probably occurred, given the normal processing of the precursors, as seen in patient 1. The ELECTRON TRANSFER FL >AVOPROTEIN DEFICIENCY 6 3 lability of ETF is likely to cause GA I1 in this patient. Although cause of the lability is not clear, the following possibilities can be considered: 1) An ETF complex cannot be formed in the mitochondria] matrix due to abnormality in the peptides of either aor 8-ETF, and the defect results in the lability of both subunits, or 2) a defect of a component required for assembly or stabilization of the ETF leads to instability of the subunits of ETF. Thus, the two above cases are new forms of ETF deficiency in GA 11.
A considerable degree of heterogeneity of expression in GA I1 patients has been reported. Clinically, GA I1 has been classified into the three groups (2): 1) neonatal onset form with congenital anomalies, such as macrocephaly, facial dysmorphism, rocker bottom feet, or polycystic kidney, 2) neonatal onset form without anomalies, and 3) mild or late onset form. Most patients with the neonatal onset form, with or without congenital anomalies, have a severe illness and often die within the 1 wk of life, or early in infancy. Other patients who survive longer can have a Reye's syndrome-like illness. On the other hand, some patients with the mild form have intermittent episodes of vomiting or hypoglycemia, and others may have no symptoms during childhood, presenting with the episodic illness in adult life (4). Loehr et al. (28) reported that five patients with an ETF-DH deficiency were cases of a neonatal onset with congenital anomalies, and that findings in two cell lines from ethylmalonic adipic aciduria (a mild form of GA 11) patients were also due to a partial deficiency of ETF-DH ( 1 2, 28). Ikeda et al. (1 3) described that all three patients showing a-ETF deficiency had the typically severe form. On the other hand, mild variants with a-ETF deficiency were also reported (14) . In patient I with the 8-ETF deficiency, the neonatal onset form without anomalies is expected to occur, and patient 2 will likely have the neonatal onset form with congenital anomalies. According to recent reviews of the phenotype in GA 11, deficiencies of ETF and ETF-DH have been noted in patients with either the severe or mild form (14, 23, 29) . On the other hand, patients with congenital anomalies such as facial dysmorphism, large head or polycystic kidney can have a deficiency of ETF, but it is less extensive than the ETF-DH deficiency (14, 29) . Thus, correlation between clinical severity and defective sites remains ambiguous.
